Research at Queen'sThe following technologies are currently available for licensing through Queen's Partnerships and innovation. If you'd like to learn more about these innovations and/or explore partnership, please reach out to our office by emailing qpi.info@queensu.ca.
| Title | Description | Opportunity |
|---|---|---|
| Antagonists of Apoptosis Inducing Factor-1, Mitochondrial (AIFM1) for Anticoronaviral Therapy | This invention presents novel small-molecule AIFM1 antagonists identified by in silico screening and validated through in vitro and in vivo studies. | Developmental Partner, Licensing, Seeking Investment |
| Minimally Invasive Ventriculoperitoneal Shunt System for Simplifying Hydrocephalus Treatment | The innovative VP shunt system represents a groundbreaking advancement in hydrocephalus treatment, addressing the challenges associated with traditional shunt designs and revision procedures. | Commercial Partner, Licensing, Seeking Investment |
| Orally Delivered Protein Treatment Protects Against Clostridioides Difficile Infection | Recent studies in Queen’s lab have identified a bacterial protease that proteolyzes and neutralizes the activity of TcdA and TcdB toxins in vitro and in vivo. The data demonstrated that oral gavage of a bacterial protease derived from commensal bacteria protected mice from developing CD disease. | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Antagonists of Dynamin-related Protein-1 (drp1) for Pulmonary Arterial Hypertension | Small molecule antagonists against drp1 offer new treatment opportunity for PAH and other diseases with increased mitochondrial fission. | Licensing, Seeking Investments |
| Novel Actin-Inhibitors for Cancer Therapy | Queen's researchers have created a series of analogs of MycB which could be used as anti-cancer agents alone or as warheads for new ADC constructs. Their effects were tested in a scalable pyrene-actin assay that measures actin polymerization. | Developmental Partner, Licensing |
| Novel Therapy for von Willebrand’s Disease and Hemophilia | Queen’s researchers have developed novel recombinant vWF and Factor VIII using ancestral sequence reconstruction. These proteins have a number of functional improvements over existing vWFs and will translate into improved therapy for both vWD and haemophilia patients. | Developmental Partner, Licensing, Seeking Investment |
| Novel Dermatological Treatment | Novel N-acyl analogs of hyaluronic acid treat skin diseases and improve wound healing. | Developmental Partner, Licensing |
| Treatment for Reducing Respiratory Distress in COVID-19 Patients | A simple LMWHA diagnostic could be used as a companion diagnostic to identify responders to N-butyryl HA therapy. | Developmental Partner, Seeking Investment |
| Novel Anti-Inflammatory Hyaluronic Acid Analogs | A broad platform technology with many cosmetic and medical uses simply by replacing existing hyaluronic acid. | Developmental Partner, Licensing |
| Novel Treatment for Gout and Hyperuricemia | Intra-articular injections of modified hyaluronic acid significantly reduces inflammation-induced swelling in gout. | Developmental Partner, Licensing |
| Novel Signal Processing Technique for Atrial Fibrillation | Use of a novel signal processing technique during atrial fibrillation to provide clinically relevant information for ablation therapy. | Developmental Partner, Commercial Partner, Licensing |
| Investigating the Role of Retinoic Acid Metabolizing Bacteria in Dysregulating the Microgut Biome in Favor of Pathogenic Species | A novel approach and corresponding compounds to treat gut diseases where retinoic acid plays a role in disease homeostasis and progression. | Commercial Partner, Licensing, Spinout, Seeking Investment |
| A Concise Approach to the Synthesis of SERCA Inhibitor Thapsigargin | Development of a new eleven step synthetic route to prepare thapsigargin and its analogs. | Developmental Partner, Licensing |
| Novel Treatment for Rheumatoid Arthritis | Novel N-butyrylated hyaluronic acid analog treats rheumatoid arthritis through both anti-inflammatory and antioxidant mechanisms | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Novel CYP26A1-Selective Inhibitors | CYP26A1 selective inhibitors enhance retinoic acid treatment efficacy and safety. | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Complex Arrythmia Activation Mapping without a Time Alignment Reference | Method for creating accurate activation timing maps to diagnose/localize cardiac arrythmia without using a time alignment reference catheter | Licensing, Seeking Investments |
| Machine Learning Approach for Diagnosing Long QT Syndrome | Novel approach for automatic ECG delineation and QT interval estimation to diagnose and classify LQT syndrome | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| MMP-14 Antibodies as Novel Therapeutics for Metastatic Cancers | Novel synthetic antibody that limits tumor progression and metastasis. | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Localized Delivery of Drugs/Biologics that are Susceptible to Degradation in Acidic Environments | A novel, injectable, liquid polymer drug delivery system intended for the localized delivery of low molecular weight chemotherapeutics, cytokines, growth factors, and other drugs/biologics susceptible to degradation in acidic environments. | Developmental Partner, Commercial Partner |
| Novel Treatment for Glioblastoma | Dichloroacetate prevents cancer cells by normalizing mitochondrial activity in glioblastoma cells, promoting apoptosis. | Licensing |
| Surgical Navigation System for Breast Cancer Surgery (Lumpectomy) | This technology uses ultrasound, electromagnetic tracking, and proprietary software to improve spatial awareness in lumpectomy surgery. | Commercial Partner, Licensing, Spinout, Seeking Investment |
| Title | Description | Opportunity |
|---|---|---|
| Optically Tracked Navigated Biopsy Capsule for Precision Brain Tumor Sampling | The novel biopsy capsule represents a paradigm shift in intraoperative tissue sampling. This advanced biopsy tool integrates optical tracking technology with an innovative capsule design that enables precise, reproducible collection of spatially-defined tissue samples from brain tumors. | Developmental Partner, Commercial Partner, Licensing |
| Advanced FISH-Based Assay for PTEN and Tumor Suppressor Gene Deletion Detection | This invention introduces a novel FISH-based assay for detecting tumor suppressor gene deletions, particularly PTEN, with significantly improved accuracy and sensitivity. The key innovation lies in the strategic design of a four-color probe set that effectively distinguishes true deletions from truncation artifacts, a common source of false positives in traditional FISH methods. | Licensing |
| Queen's Cardio Pulmonary Unit | Offering advanced cardiopulmonary research facilities including transcriptomics, proteomic, imaging, and clinical trial support. | Commercial Partner |
| Precision Deparaffinization for Sample Analysis and Preservation | This stand-alone technology facilitates selective melting of paraffin from tissue samples, enabling spot deparaffinization without compromising sample integrity. | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Non-Invasive Intraocular Pressure Monitoring Soft Contact Lens | Queen’s researchers have developed multiple novel designs of soft contact lensesfor continuous measurement of IOP. These designs are protected by two separate patent applications with two granted US patents off the initial patent application. | Developmental Partner, Spinout, Seeking Investment |
| DNA Methylation-Based Liquid Biopsy for Monitoring of Metastatic Triple-Negative Breast Cancer (mTNBC) | The mDETECT assay is a sensitive, quantitative, and rapid method of assessing tumour burden. It provides accurate results in weeks to identify effective treatments. It is currently being developed as a platform technology with tests undergoing clinical validation in breast, lung, prostate, pancreatic and ovarian cancer. It is currently being developed as a platform technology with 6 cancer tests including uveal melanoma, a rare tumor of the eye. | Developmental Partner, Spinout, Seeking Investment |
| Prostate Cancer Biomarker Assay | A methylated DNA classifier to identify prostate cancer with over 90% sensitivity and specificity. | Developmental Partner, Licensing, Seeking Investment |
| Novel Prognostic Tool for ER+ Breast Cancer | Glucocorticoid Receptor promoter methylation has both positive and negative prognostic value for ER+ breast cancer patients | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Diagnosing Cognitive Impairment after COVID-19 Infection | Eye-tracking as a non-invasive tool capable of identifying COVID-19 patients at risk for neurological impairments. | Developmental Partner, Spinout, Seeking Investment |
| Complex Arrythmia Activation Mapping without a Time Alignment Reference | Method for creating accurate activation timing maps to diagnose/localize cardiac arrythmia without using a time alignment reference catheter | Licensing, Seeking Investments |
| Novel Diagnostic for Identifying and Classifying Neuroendocrine Neoplasms | A microRNA‑based hierarchical classifier which can both identify and sub-classify neuroendocrine neoplasms (NENs). | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Title | Description | Opportunity |
|---|---|---|
| Queen's Cardio Pulmonary Unit | Offering advanced cardiopulmonary research facilities including transcriptomics, proteomic, imaging, and clinical trial support. | Commercial Partner |
| Diagnosing Cognitive Impairment after COVID-19 Infection | Eye-tracking as a non-invasive tool capable of identifying COVID-19 patients at risk for neurological impairments. | Developmental Partner, Spinout, Seeking Investment |
| Novel Signal Processing Technique for Atrial Fibrillation | Use of a novel signal processing technique during atrial fibrillation to provide clinically relevant information for ablation therapy. | Developmental Partner, Commercial Partner, Licensing |
| Machine Learning Approach for Diagnosing Long QT Syndrome | Novel approach for automatic ECG delineation and QT interval estimation to diagnose and classify LQT syndrome. | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Generating ECG/EKG Signals from PPG Sensor Data | To address the limitations of heart monitoring using PPG, researchers at Queen’s University have developed a technique for generating detailed ECG/EKG signals from corresponding PPG signals using a deep learning approach. | Developmental Partner, Commercial Partner |
| Title | Description | Opportunity |
|---|---|---|
| DNA Methylation-Based Liquid Biopsy for Monitoring of Metastatic Triple-Negative Breast Cancer (mTNBC) | The mDETECT assay is a sensitive, quantitative, and rapid method of assessing tumour burden. It provides accurate results in weeks to identify effective treatments. It is currently being developed as a platform technology with tests undergoing clinical validation in breast, lung, prostate, pancreatic and ovarian cancer. It is currently being developed as a platform technology with 6 cancer tests including uveal melanoma, a rare tumor of the eye. | Developmental Partner, Spinout, Seeking Investment |
| Novel Actin-Inhibitors for Cancer Therapy | Queen's researchers have created a series of analogs of MycB which could be used as anti-cancer agents alone or as warheads for new ADC constructs. Their effects were tested in a scalable pyrene-actin assay that measures actin polymerization. | Developmental Partner, Licensing |
| Prostate Cancer Biomarker Assay | A methylated DNA classifier to identify prostate cancer with over 90% sensitivity and specificity. | Developmental Partner, Licensing, Seeking Investment |
| Hippo Pathway Bioluminescent Biosensor | Novel Hippo pathway biosensors for drug screening and quantitative monitoring of Hippo pathway components. | Developmental Partner, Commercial Partner, Licensing |
| A Concise Approach to the Synthesis of SERCA Inhibitor Thapsigargin | Development of a new eleven step synthetic route to prepare thapsigargin and its analogs. | Developmental Partner, Licensing |
| Novel CYP26A1-Selective Inhibitors | CYP26A1 selective inhibitors enhance retinoic acid treatment efficacy and safety. | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| MMP-14 Antibodies as Novel Therapeutics for Metastatic Cancers | Novel synthetic antibody that limits tumor progression and metastasis. | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Novel Diagnostic for Identifying and Classifying Neuroendocrine Neoplasms | A microRNA‑based hierarchical classifier which can both identify and sub-classify neuroendocrine neoplasms (NENs). | Developmental Partner, Commercial Partner, Licensing, Seeking Investment |
| Novel Treatment for Glioblastoma | Dichloroacetate prevents cancer cells by normalizing mitochondrial activity in glioblastoma cells, promoting apoptosis. | Licensing |
| Surgical Navigation System for Breast Cancer Surgery (Lumpectomy) | This technology uses ultrasound, electromagnetic tracking, and proprietary software to improve spatial awareness in lumpectomy surgery. | Commercial Partner, Licensing, Spinout, Seeking Investment |